Galderma Group
GALD.SWGALD.SW · Stock Price
Historical price data
Overview
Galderma's mission is to advance dermatology for every skin story, leveraging its position as the sole global, scaled pure-play in the field. Its key achievement is building an integrated, three-pillar business model—Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare—that drives growth across medical and consumer markets. The strategy centers on innovation through a proprietary R&D engine, global commercial execution, and capitalizing on its independence post-2019 Nestlé separation and successful 2024 IPO. This approach has established a leading portfolio with strong brand recognition and a robust pipeline.
Technology Platform
Integrated platform combining advanced formulation & drug delivery science for topicals, proprietary biomaterial engineering for injectable aesthetics, and deep translational research in skin biology.
Funding History
2FDA Approved Drugs
20Company Timeline
Founded in Lausanne, Switzerland
Debt: $2.5B
FDA Approval: TWYNEO
FDA Approval: EPSOLAY
IPO — $2.3B
FDA Approval: NEMLUVIO